Aurobindo Pharma Ltd vs Vivanza Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 11, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1465 as of 11 Jun 14:42 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Vivanza Biosciences Ltd changed from 687.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Vivanza Biosciences Ltd changed from ₹ 52.24 crore on March 2021 to ₹ 7.96 crore on March 2025 . This represents a CAGR of -31.36% over 5 years The revenue of Aurobindo Pharma Ltd for the Mar '26 is ₹ 8970 crore as compare to the Dec '25 revenue of ₹ 8833 crore. This represent the growth of 1.54% The revenue of Vivanza Biosciences Ltd for the Mar '26 is ₹ 6.37 crore as compare to the Dec '25 revenue of ₹ 45.33 crore. This represent the decline of -85.95% The ebitda of Aurobindo Pharma Ltd for the Mar '26 is ₹ 1867 crore as compare to the Dec '25 ebitda of ₹ 1896 crore. This represent the decline of -1.51% The ebitda of Vivanza Biosciences Ltd for the Mar '26 is ₹ -0.22 crore as compare to the Dec '25 ebitda of ₹ 0.29 crore. This represent the decline of -175% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 920.84 crore over 8 quarters. This represents a CAGR of 0.14% The net profit of Vivanza Biosciences Ltd changed from ₹ 0.27 crore to ₹ -0.45 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Vivanza Biosciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Vivanza Biosciences Ltd

Vivanza Biosciences Limited, formerly known as Ivee Injectaa Limited was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992.
Due to recessionary trends which lead to difficult business conditions in year 1999-2000, the parenteral industry suffered a setback and due to this, the name of the Company was changed from Ivee Injectaa Limited to Vivanza Biosciences Limited in 2015. The Company is focused in commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines.
It is presently engaged in the business of Pharmaceutical Products. Head quartered in Gujarat, India, Company came into existence in April 2016 to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system.

FAQs for the comparison of Aurobindo Pharma Ltd and Vivanza Biosciences Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Vivanza Biosciences Ltd?

Market cap of Aurobindo Pharma Ltd is 84,442 Cr while Market cap of Vivanza Biosciences Ltd is 6 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Vivanza Biosciences Ltd?

The stock performance of Aurobindo Pharma Ltd and Vivanza Biosciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Vivanza Biosciences Ltd?

As of June 11, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1453.9. On the other hand, Vivanza Biosciences Ltd stock price is INR ₹1.71.

How do dividend payouts of Aurobindo Pharma Ltd and Vivanza Biosciences Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Vivanza Biosciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.